Author

N. Fenderico

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

I. Jordens· 2 shared J. M. Bugter· 2 shared M. M. Maurice· 2 shared A. D. Campbell· 1 shared A. Venhuizen· 1 shared B.-K. Koo· 1 shared D. Kokkinidi· 1 shared D. Montiel Gonzalez· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Jordens

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mutation-induced phenotypic plasticity drives formation of a pro-metastatic tumour-intrinsic niche

J. M. Bugter, L. El Bouazzaoui, E. Kucukkose, M. L. Mills, Y. Hong, J. Sprangers, I. Jordens, D. Kokkinidi, S. Plugge, A. Venhuizen, S. Bosman, J. Hageman, N. Fenderico, K. Gilroy, D. Montiel Gonzalez, , M. M. Maurice

This study identifies mutation-induced phenotypic plasticity as a driver of a pro-metastatic tumour-intrinsic niche in BRAF-mutant colorectal cancer.

bioRxiv · Dec 22, 2022 · PreprintCancer Biology

RNF43 truncating mutations mediate a tumour suppressor-to-oncogene switch to drive niche-independent self-renewal in cancer

M. Spit, N. Fenderico, I. Jordens, T. Radaszkiewicz, R. G. H. Lindeboom, J. M. Bugter, L. Ootes, M. van Osch, E. Janssen, K. E. Boonekamp, K. Hanakova, D. Potesil, Z. Zdrahal, S. F. Boj, J. P. Medema, , M. M. Maurice

This study identifies RNF43 truncating mutations that switch from tumor suppressor to oncogene, enabling niche-independent self-renewal in cancer and resistance to anti-Wnt therapy.

bioRxiv · Sep 1, 2019Cancer Biology